Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK

World Journal of Gastroenterology

Volumn 12, Issue 43, 2006, Pages 7007-7011

  Tonus, Carolin ^a   Neupert, Gero ^b   Sellinger, Markus ^c  

^a Herz Jesu Krankenhaus Fulda   (Germany)

^b Offenbach Hospital   (Germany)

^c Medical Practice for Gastroenterology and Hepatology   (Germany)

Author keywords

Adenoma; Cancer screening; Colon cancer; Feces; Pyruvate kinase type M2; Rectal cancer; Tumor M2 Pyruvate Kinase

Indexed keywords

BIOLOGICAL MARKER; PYRUVATE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SCREENING; CANCER STAGING; CLINICAL PRACTICE; COLON CARCINOMA; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PATIENT SELECTION; RECTUM CARCINOMA; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

EID: 33751513942     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i43.7007     Document Type: Article

References (38)

1. Krebs in Deutschland, Häufigkeit und Trends, Robert Koch Institut, 5. überarbeitete, aktualisierte Ausgabe, Saarbrücken 2006. Available from: URL: http://www.rki.de/cln_006/nn_226978/DE/Content/ GBE/DachdokKrebs/Broschuere/ kid2006,templateId=raw,property=publicationFile.pdf/kid2006
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Cin 2005; 55: 74-108
3. Darmkrebs-wenig Resonanz auf Angebot zur Früherkennung, Ärztezeitung, 2004-10-27. Available from: URL: http://www.aerztezeitung.de/docs/2004/10/27/195a0401.asp
4. Macrae FA, St John DJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-898
5. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477
6. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-437
7. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560
8. Koss K, Maxton D, Jankowski JAZ. The potential use of fecal dimeric M2 pyruvate kinase (Tumour M2-PK) in screening for colorectal cancer (CRC). In: Poster Abstracts and Trade Exhibition Book: NCRI Cancer Conference; 2005 Oct 2-5; Birmingham, UK. London: Callisto, 2005: 199
9. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-159
10. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-428
11. Ewald N, Toepler M, Akinci A, Kloer HU, Bretzel RG, Hardt PD. Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data. Z Gastroenterol 2005; 43: 1313-1317
12. Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls. Anticancer Res 2003; 23: 851-853
13. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU. Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 2004; 91: 980-984
14. McLoughlin R, Shiel E, Sebastian S, Ryan B, O'Connor HJ, O'Morain C. Tumor M2-PK, a novel screening tool for colorectal cancer. In: Poster Abstracts and Trade Exhibition Book: NCRI Cancer Conference; 2005 Oct 2-5; Birmingham, UK. London: Callisto, 2005: 202
15. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H, Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev Oncog 1992; 3: 91-115
16. Reinacher M, Eigenbrodt E. Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol 1981; 37: 79-88
17. Board M, Humm S, Newsholme EA. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem J 1990; 265: 503-509
18. Hacker HJ, Steinberg P, Bannasch P. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 1998; 19: 99-107
19. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA. Hypoxia regulates beta-enolase and pyruvate kinase-M promoters by modulating Sp1/ Sp3 binding to a conserved GC element. J Biol Chem 1998; 273: 26087-26093
20. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998; 8: 588-594
21. Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E. Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 2001; 20: 6891-6898
22. Nishikawa T, Maemura K, Hirata I, Matsuse R, Morikawa H, Toshina K, Murano M, Hashimoto K, Nakagawa Y, Saitoh O, Uchida K, Katsu K. A simple method of detecting K-ras point mutations in stool samples for colorectal cancer screening using one-step polymerase chain reaction/ restriction fragment length polymorphism analysis. Clin Chim Acta 2002; 318: 107-112
23. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005; 15: 300-308
24. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 1999; 19: 2599-2601
25. Wechsel HW, Petri E, Bichler KH, Feil G. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK). Anticancer Res 1999; 19: 2583-2590
26. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000; 20: 5077-5082
27. Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prev 2000; 24: 531-535
28. Kaura B, Bagga R, Patel FD. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma. J Obstet Gynaecol Res 2004; 30: 193-196
29. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004; 49: 1149-1155
30. Zhang B, Chen JY, Chen DD, Wang GB, Shen P. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls. World J Gastroenterol 2004; 10: 1643-1646
31. Naumann M, Schaum B, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein J. Faecal pyruvate kinase type M2 - a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr 2004; 129: 1806-1807
32. Schmiegel W, Selbmann HK. Leitlinie "Kolorektales Karzinom: Prevention, Diagnostik and Therapie 2004" Im Auftrag der Deutschen Gesellschaft für Verdauungs- and Stoffwechselkrankheiten mit Unterstützung der Deutschen Krebshilfe. Available from: http://www.dgvs.de/322.php#Leitlinie_Kolorektales_Karzinom_Prvention_ Diagnostik_und_Therapie_2004
33. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 2006; 56: 11-25; quiz 49-50
34. Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res 2001; 7: 590-593
35. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR, Boynton K, Kinzler KW, Vogelstein B. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359: 403-404
36. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-1227
37. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman SN, D'Allessio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B, Jen J. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 858-865
38. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53